

# Prof. Dr. Andreas ROSENWALD

Vorstand des Instituts für Pathologie, Universität Würzburg

## Publikationsliste

### 2019

1. Giovanni Almanzar, Marc Schmalzing, Matthias Klein, Deborah Hilligardt, Patrick Morris, Kerstin Höfner, Nady El Hajj, Hermann Kneitz, Vanessa Wild, **Andreas Rosenwald**, Sandrine Benoit, Henning Hamm, Hans-Peter Tony, Thomas Haaf, Matthias Goebeler, Martina Prelog  
Memory CD4+ T Cells Lacking Expression of CCR7 Promote Pro-Inflammatory Cytokine Production in Patients With Diffuse Cutaneous Systemic Sclerosis  
Eur J Dermatol Actions , 29 (5), 468-476 2019 Oct 1. JIF18: 3.094
2. Almanzar G., Schmalzing M., Klein M., Hilligardt D., Morris P., Höfner K., Hajj N.E., Kneitz H., Wild V., **Rosenwald A.**, Benoit S, Hamm H, Tony HP, Haaf T, Goebeler M, Prelog M. Memory CD4+ T cells lacking expression of CCR7 promote pro-inflammatory cytokine production in patients with diffuse cutaneous systemic sclerosis. Eur J Dermatol. 2019 Oct 1;29(5):468-476. JIF18: 3.094
3. Amador C., Greiner T.C., Heavican T.B., Smith L.M., Galvis K.T., Lone W.G., Bouska A., D'amore F., Bjerregård Pedersen M., Pileri S.A., Agostinelli C., Feldman A.L., **Rosenwald A.**, Ott G., Mottok A., Savage K.J., de Leval L., Gaulard P., Lim S.T., Ong C.K., Ondrejka S.L., Song J., Campo E., Jaffe E.S., Staudt L.M., Rimsza L.M., Vose J., Weisenburger D.D., Chan W.C., Iqbal J.  
Reproducing the Molecular Subclassification of Peripheral T-cell Lymphoma-NOS by Immunohistochemistry.  
Blood. 2019 Sep 27. [Epub ahead of print]. JIF18: 16.601
4. Barrio S., Munawar U., Zhu Y.X., Giesen N., Shi C.X., Da Viá M., Sanchez R., Bruins L., Demler T., Müller N., Haertle L., Garitano A., Steinbrunn T., Danhof S., Cuenca I., Barrio-Garcia C., Braggio E., **Rosenwald A.**, Martinez-Lopez J., Rasche L., Raab M.S., Stewart A.K., Einsele H., Stühmer T., Kortüm K.M.  
KZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma.  
Haematologica. 2019 Sep 26. [Epub ahead of print] JIF18: 9.944
5. Barrio S., Stühmer T., Da-Viá M., Barrio-Garcia C., Lehnert N., Besse A., Cuenca I., Garitano-Trojaola A., Fink S., Leich E., Chatterjee M., Driessen C., Martinez-Lopez J., **Rosenwald A.**, Beckmann R., Bargou R.C., Braggio E., Stewart A.K., Raab M.S., Einsele H., Kortüm K.M.

- Spectrum and functional validation of PSMB5 mutations in multiple myeloma. *Leukemia*. 2019 Feb;33(2):447-456. Epub 2018 Jul 19. JIF18: 9.944
6. Carreras J., Lopez-Guillermo A., Kikuti Y.Y., Itoh J., Masashi M., Ikoma H., Tomita S., Hiraiwa S., Hamoudi R., **Rosenwald A.**, Leich E., Martinez A., Roncador G., Villamor N., Colomo L., Perez P., Tsuji N.M., Campo E., Nakamura N.  
High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.  
*J Clin Exp Hematop*. 2019;59(1):1-16. JIF18: 0.205
  7. Dugge R., Kreipe H., **Rosenwald A.**, Lehmann U., Möller P., Barth T.F.E., Erlemann R.  
Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis.  
*Ann Hematol*. 2019 Feb;98(2):515-517. Epub 2018 Jul 7. JIF18: 2.850
  8. Fogt F., Ruediger T., Augustin A.J., Frank D.M., **Rosenwald A.**, Wellmann A, Lee V.  
Isolated Intraocular Rosai-Dorfman Disease. *Ocul Oncol Pathol*. 2019 Oct;5(6):418-423. Epub 2019 Apr 10.
  9. Friedrichs B., Nickelsen M., Ziepert M., Altmann B., Haenel M., Viardot A., Schmidt C., Ruebe C., Loeffler M., Pfreundschuh M., **Rosenwald A.**, Glass B., Lenz G., Schmitz N; German high-grade lymphoma Study Group.  
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.  
*Br J Haematol*. 2019 Mar;184(5):760-768. Epub 2018 Dec 5. JIF18: 5.206
  10. Fuchs M., Goergen H., Kobe C., Kuhnert G., Lohri A., Greil R., Sasse S., Topp M.S., Schäfer E., Hertenstein B., Soekler M., Vogelhuber M., Zijlstra J.M., Keller U.B., Krause S.W., Wilhelm M., Maschmeyer G., Thiemer J., Dührsen U., Meissner J., Viardot A., Eich H., Baues C., Diehl V., **Rosenwald A.**, von Tresckow B., Dietlein M., Borchmann P., Engert A.  
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.  
*J Clin Oncol*. 2019 Sep 10. [Epub ahead of print] JIF18: 28.349
  11. Hartmann S., Plütschow A., Mottok A., Bernd H.W., Feller A.C., Ott G., Cogliatti S., Fend F., Quintanilla-Martinez L., Stein H., Klapper W., Möller P., **Rosenwald A.**, Engert A., Hansmann M.L., Eichenauer D.A.  
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.  
*Am J Hematol*. 2019 Aug. [Epub ahead of print] JIF18: 6.137
  12. Heavican T.B., Bouska A., Yu J., Lone W., Amador C., Gong Q., Zhang W., Li Y., Dave B.J., Nairismägi M.L., Greiner T.C., Vose J., Weisenburger D.D., Lachel C., Wang C., Fu K., Stevens J.M., Lim S.T., Ong C.K., Gascoyne R.D., Missiaglia E., Lemonnier F., Haioun C., Hartmann S., Pedersen M.B., Laginestra M.A., Wilcox R.A., Teh B.T., Yoshida N., Ohshima K., Seto M., **Rosenwald A.**, Ott G., Campo E., Rimsza L.M., Jaffe E.S., Braziel

R.M., d'Amore F., Inghirami G., Bertoni F., de Leval L., Gaulard P., Staudt L.M., McKeithan T.W., Pileri S., Chan W.C., Iqbal J.  
 Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.  
 Blood. 2019 Feb 19. [Epub ahead of print] JIF18: 16.601

### **Buchbeitrag**

13. G. Höfler, H. Kreipe, H. Moch (Hrsg.), **A. Rosenwald**  
 Pathologie. Das Lehrbuch. 6. A., 2019
  
14. Hrudka J., Eis V., Heřman J., Prouzová Z., **Rosenwald A.**, Duška F.  
 Panniculitis-like T-cell-lymphoma in the mesentery associated with hemophagocytic syndrome: autopsy case report.  
 Diagn Pathol. 2019 Jul 17;14(1):80. JIF18: 2.528
  
15. Jain N., Hartert K., Tadros S., Fiskus W., Havranek O., Ma M.C.J., Bouska A., Heavican T., Kumar D., Deng Q., Moore D., Pak C., Liu C.L., Gentles A.J., Hartmann E., Kridel R., Smedby K.E., Juliusson G., Rosenquist R., Gascoyne R.D., **Rosenwald A.**, Giacotti F., Neelapu S.S., Westin J., Vose J.M., Lunning M.A., Greiner T., Rodig S., Iqbal J., Alizadeh A.A., Davis R.E., Bhalla K., Green M.R.  
 Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.  
 Sci Transl Med. 2019 Jun 19;11(497). JIF18: 17.200
  
16. Kircher S., Stolzenburg A., Kortüm K.M., Kircher M., Da Via M., Samnick S., Buck A.K., Einsele H., **Rosenwald A.**, Lapa C.  
 Hexokinase-2 Expression in 11C-Methionine-Positive, 18F-FDG-Negative Multiple Myeloma.  
 J Nucl Med. 2019 Mar;60(3):348-352. JIF18: 7.308
  
17. Lapa C., Lückerath K., Kircher S., Hänscheid H., Grigoleit G.U., **Rosenwald A.**, Stolzenburg A., Kropf S., Einsele H., Wester H.J., Buck A.K., Kortüm K.M., Schirbel A.  
 Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy.  
 Br J Haematol. 2019 Feb;184(3):440-443. Epub 2018 Jan 24. JIF18: 5.206
  
18. Loeffler-Wirth H., Kreuz M., Hopp L., Arakelyan A., Haake A., Cogliatti S.B., Feller A.C., Hansmann M.L., Lenze D., Möller P., Müller-Hermelink H.K., Fortenbacher E., Willscher E., Ott G., **Rosenwald A.**, Pott C., Schwaenen C., Trautmann H., Wessendorf S., Stein H., Szczepanowski M., Trümper L., Hummel M., Klapper W., Siebert R., Loeffler M., Binder H., German Cancer Aid consortium Molecular Mechanisms for Malignant Lymphoma.  
 A modular transcriptome map of mature B cell lymphomas.  
 Genome Med. 2019 Apr 30;11(1):27. JIF18: 10.886

19. Longerich T., Endris V., Neumann O., Rempel E., Kirchner M., Abadi Z., Uhrig S., Kriegsmann M., Weiss K.H., Breuhahn K., Mehrabi A., Weber T.F., Wilkens L., Straub B.K., **Rosenwald A.**, Schulze F., Brors B., Froehling S., Pellegrino R., Budczies J., Schirmacher P., Stenzinger A.  
RSPO2 gene rearrangement: a powerful driver of  $\beta$ -catenin activation in liver tumours.  
Gut. 2019 Feb 2. [Epub ahead of print] JIF18: 17.943
20. López C., Kleinheinz K., Aukema S.M., Rohde M., Bernhart S.H., Hübschmann D., Wagener R., Toprak U.H., Raimondi F., Kreuz M., Waszak S.M., Huang Z., Sieverling L., Paramasivam N., Seufert J., Sungalee S., Russell R.B., Bausinger J., Kretzmer H., Ammerpohl O., Bergmann A.K., Binder H., Borkhardt A., Brors B., Claviez A., Doose G., Feuerbach L., Haake A., Hansmann M.L., Hoell J., Hummel M., Korbel J.O., Lawrenz C., Lenze D., Radlwimmer B., Richter J., Rosenstiel P., **Rosenwald A.**, Schilhabel M.B., Stein H., Stilgenbauer S., Stadler P.F., Szczepanowski M., Weniger M.A., Zapatka M., Eils R., Lichter P., Loeffler M., Möller P., Trümper L., Klapper W.; ICGC MMML-Seq Consortium, Hoffmann S., Küppers R., Burkhardt B., Schlesner M., Siebert R.  
Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma.  
Nat Commun. 2019 Mar 29;10(1) JIF18: 11.878
21. Martín-García D., Navarro A., Valdés-Mas R., Clot G., Gutiérrez-Abril J., Prieto M., Ribera-Cortada I., Woroniecka R., Rymkiewicz G., Bens S., de Leval L., **Rosenwald A.**, Ferry J.A., Hsi E.D., Fu K., Delabie J., Weisenburger D., de Jong D., Climent F., O'Connor S.J., Swerdlow S.H., Torrents D., Beltran S., Espinet B., González-Farré B., Veloza L., Costa D., Matutes E., Siebert R., Ott G., Quintanilla-Martinez L., Jaffe E.S., López-Otín C., Salaverria I., Puente X.S., Campo E., Beà S.  
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.  
Blood. 2019 Feb 28;133(9):940-951. JIF18: 16.601
22. Mellert K., Martin M., Lennerz J.K., Lüdeke M., Staiger A.M., Kreuz M., Löffler M., Schmitz N., Trümper L., Feller A.C., Hartmann S., Hansmann M.L., Klapper W., Stein H., **Rosenwald A.**, Ott G., Ziepert M., Möller P.  
The impact of SOCS1 mutations in diffuse large B-cell lymphoma.  
Br J Haematol. 2019 Aug 12. [Epub ahead of print] JIF18: 5.206
23. Mendeville M., Roemer M.G.M., van den Hout M.F.C.M., Los-de Vries G.T., Bladergroen R., Stathi P., Hijmering N.J., **Rosenwald A.**, Ylstra B., de Jong D.  
Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma.  
Blood. 2019 Jan 24;133(4):377-380. Epub 2018 Dec 3. JIF18: 16.601
24. Ott G., Klapper W., Feller A.C., Hansmann M.L., Möller P., Stein H., **Rosenwald A.**, Fend F.  
[Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?]  
[Article in German]

Pathologe. 2019 Mar;40(2):157-168. JIF18: 0.546

25. Pattschull G., Walz S., Gründl M., Schwab M., Rühl E., Baluapuri A., Cindric-Vranesic A., Kneitz S., Wolf E., Ade C.P., **Rosenwald A.**, von Eyss B., Gaubatz S.  
The Myb-MuvB Complex Is Required for YAP-Dependent Transcription of Mitotic Genes.  
Cell Rep. 2019 Jun 18;27(12):3533-3546. JIF18: 7.815
  
26. Rauert-Wunderlich H., Mottok A., Scott D.W., Rimsza L.M., Ott G., Klapper W., Unterhalt M., Kluin-Nelemans H.C., Hermine O., Hartmann S., Thorns C., Rymkiewicz G., Holte H., Dreyling M., Hoster E., **Rosenwald A.**  
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.  
Br J Haematol. 2019 Feb;184(4):616-624. Epub 2018 Aug 10. JIF18: 5.206
  
27. Riabinska A., Lehrmann D., Jachimowicz R.D., Knittel G., Fritz C., Schmitt A., Geyer A., Heneweer C., Wittersheim M., Frenzel L.P., Torgovnick A., Wiederstein J.L., Wunderlich C.M., Ortmann M., Paillard A., Wößmann W., Borkhardt A., Burdach S., Hansmann M.L., **Rosenwald A.**, Perner S., Mall G., Klapper W., Merseburg A., Krüger M., Grüll H., Persigehl T., Wunderlich F.T., Peifer M., Utermöhlen O., Büttner R., Beleggia F., Reinhardt H.C.  
ATM activity in T cells is critical for immune surveillance of lymphoma in vivo.  
Leukemia. 2019 Nov 5. [Epub ahead of print] JIF18: 9.944
  
28. Richter J., Hüttmann A., Rekowski J., Schmitz C., Gärtner S., **Rosenwald A.**, Hansmann M.L., Hartmann S., Möller P., Wacker H.H., Feller A., Thorns C., Müller S., Dührsen U., Klapper W.  
Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome.  
Blood Cancer J. 2019 Aug 19;9(9):67. JIF18: 7.895
  
29. Roisman A., Castellano G., Navarro A., Gonzalez-Farre B., Pérez-Galan P., Esteve-Codina A., Dabad M., Heath S., Gut M., Bosio M., Bellot P., Salembier P., Oliveras A., Slavutsky I., Magnano L., Horn H., **Rosenwald A.**, Ott G., Aymerich M., López-Guillermo A., Jares P., Martín-Subero J.I., Campo E., Hernández L.  
Differential expression of long non-coding RNAs are related to proliferation and histological diversity in follicular lymphomas.  
Br J Haematol. 2019 Feb;184(3):373-383. Epub 2018 Nov 22. JIF18: 5.206
  
30. **Rosenwald A.**, Bens S., Advani R., Barrans S., Copie-Bergman C., Elsensohn M.H., Natkunam Y., Calaminici M., Sander B., Baia M., Smith A., Painter D., Pham L., Zhao S., Ziepert M., Jordanova E.S., Molina T.J., Kersten M.J., Kimby E., Klapper W., Raemaekers J., Schmitz N., Jardin F., Stevens W.B.C., Hoster E., Hagenbeek A., Gribben J.G., Siebert R., Gascoyne R.D., Scott D.W., Gaulard P., Salles G., Burton C., de Jong D., Sehn L.H., Maucort-Boulch D.

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

J Clin Oncol. 2019 Sep 9. [Epub ahead of print] JIF18: 28.349

31. Schmidt S., Gay D., Uthe F.W., Denk S., Paauwe M., Matthes N., Diefenbacher M.E., Bryson S., Warrander F.C., Erhard F., Ade C.P., Baluapuri A., Walz S., Jackstadt R., Ford C., Vlachogiannis G., Valeri N., Otto C., Schülein-Völk C., Maurus K., Schmitz W., Knight J.R.P., Wolf E., Strathdee D., Schulze A., Germer C.T., **Rosenwald A.**, Sansom O.J., Eilers M., Wiegering A.

A MYC-GCN2-eIF2 $\alpha$  negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer.

Nat Cell Biol. 2019 Nov 4. [Epub ahead of print]. JIF18: 17.728

32. Schollbach J., Kircher S., Wiegering A., Seyfried F., Klein I., **Rosenwald A.**, Germer C.T., Löb S.

Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe? Cancer Immunol Immunother. 2019 Jan 22 [Epub ahead of print]. JIF18: 4.900

33. Seibold M., Stühmer T., Kremer N., Mottok A., Scholz C.J., Schlosser A., Leich E., Holzgrabe U., Brünnert D., Barrio S., Kortüm K.M., Solimando A.G., Chatterjee M., Einsele H., **Rosenwald A.**, Bargou R.C., Steinbrunn T.

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.

Haematologica. 2019 Oct 10. [Epub ahead of print]. JIF18: 7.570

34. Sibon D., Nguyen D.P., Schmitz N., Suzuki R., Feldman A.L., Gressin R., Lamant L., Weisenburger D.D., **Rosenwald A.**, Nakamura S., Ziepert M., Maurer M.J., Bast M., Armitage J.O., Vose J.M., Tilly H., Jais J.P., Savage K.J.

ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.

Haematologica. 2019 Apr 19. [Epub ahead of print] JIF18: 7.570

35. Staiger A.M., Altenbuchinger M., Ziepert M., Kohler C., Horn H., Huttner M., Hüttl K.S., Glehr G., Klapper W., Szczepanowski M., Richter J., Stein H., Feller A.C., Möller P., Hansmann M.L., Poeschel V., Held G., Loeffler M., Schmitz N., Trümper L., Pukrop T., **Rosenwald A.**, Ott G., Spang R.; Emed Demonstrator Project; German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.

Leukemia. 2019 Sep 17. [Epub ahead of print] JIF18: 9.944

36. Staiger A.M., Hoster E., Jurinovic V., Winter S., Leich E., Kalla C., Möller P., Bernd H.W., Feller A.C., Koch K., Klapper W., Stein H., Hansmann M.L., Hartmann S., Dreyling M., Weigert O., Hiddemann W., Herfarth K., **Rosenwald A.**, Engelhard M., Ott G., Horn H.

Localized and Advanced Stage Follicular Lymphomas Differ in their Gene Expression Profiles.

Blood. 2019 Oct 10. [Epub ahead of print]. JIF18: 16.601

37. Steen C.B., Leich E., Myklebust J.H., Lockmer S., Wise J.F., Wahlin B.E., Østenstad B., Liestøl K., Kimby E., **Rosenwald A.**, Smeland E.B., Holte H., Lingjærde O.C., Brodtkorb M.

A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Haematologica. 2019 Mar 7. JIF18: 7.570

38. Stein R.G., Ebert S., Schlahsa L., Scholz C.J., Braun M., Hauck P., Horn E., Monoranu C.M., Thiemann V.J., Wustrow M.P., Häusler S.F., Montalban Del Barrio I., Stueber T.N., Wöfl M., Dietl J., **Rosenwald A.**, Diessner J.E., Wöckel A., Wischhusen J.

Cognate Non-Lytic Interactions between CD8+ T cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties.

Cancer Res. 2019 Jan 28. [Epub ahead of print]. JIF18: 8.378

39. Tanaka Y., Momose S., Tabayashi T., Sawada K., Yamashita T., Higashi M., Sagawa M., Tokuhira M., **Rosenwald A.**, Kizaki M., Tamaru J.I.

Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.

Cancer Sci. 2019 Dec 17. [Epub ahead of print]. JIF18: 4.751

40. Wallaschek N., Niklas C., Pompaiah M., Wiegering A., Germer C.T., Kircher S., Brändlein S., Maurus K., **Rosenwald A.**, Yan H.H.N., Leung S.Y., Bartfeld S.

Establishing Pure Cancer Organoid Cultures: Identification, Selection and Verification of Cancer Phenotypes and Genotypes.

J Mol Biol. 2019 May 29. JIF18: 5.067

## 2018

1. Appenzeller S., Gesierich A., Thiem A., Hufnagel A., Jessen C., Kneitz H., Regensburger M., Schmidt C., Zirkenbach V., Bischler T., Schilling B., Siedel C., Goebeler M.E., Houben R., Schrama D., Gehrig A., Rost S., Maurus K., Bargou R., **Rosenwald A.**, Scharl M., Goebeler M., Meierjohann S.

The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.

Cancer. 2018 Dec 18. doi: 10.1002/cncr.31843. [Epub ahead of print]

2. Aukema, S.M., Hoster, E., **Rosenwald, A.**, Canoni, D., Delfau-Larue, M.H., Rymkiewicz, G., Thorns, C., Hartmann, S., Kluin-Nelemans, H., Hermine, O., Dreyling, M., Klapper, W.

Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.

Blood. 2018 Jan 25;131(4): S. 417-420